Correlation Between the Triglyceride-glucose Index and the Onset of Atrial Fibrillation in Patients with Non-alcoholic Fatty Liver Disease

Overview

Journal Diabetol Metab Syndr

Publisher Biomed Central

Specialty Endocrinology

Date 2023 May 9

PMID 37158953

Authors

Yao Zhang

Leigang Wang

Jiaxin Qi

Bing Yu

Jianqi Zhao

Lin Pang

Wenjing Zhang

Liang Bin

Affiliations

Soon will be listed here.

Abstract

Background: Non-alcoholic fatty liver disease (NAFLD) is associated with atrial fibrillation (AF). Insulin resistance (IR) is the main cause of the high prevalence of AF in NAFLD patients. The triglyceride-glucose index (TyG) is a novel IR-related indicator implicated in the incidence and severity of NAFLD. However, the role of TyG in determining the risk for AF in patients with NAFLD remains unclear.

Methods: A retrospective study was conducted on 912 patients diagnosed with NAFLD via ultrasonography. These patients were divided into two groups: (1) NAFLD+ AF and (2) NAFLD+ non-AF. Least Absolute Shrinkage and Selection Operator (LASSO) regression was used to assess the correlation between the TyG index and the high risk for AF. A receiver operating characteristic (ROC) curve was constructed to evaluate the predictive value for the TyG index for AF. Restricted cubic splines (RCS) were used to test the linear correlation between TyG and the risk for AF.

Results: A total of 204 patients with AF and 708 patients without AF were included in this study. The LASSO logistic regression analysis showed that TyG was an independent risk factor for AF (odds ratio [OR] = 4.84, 95% confidence interval [CI] 2.98-7.88, P < 0.001). The RCS showed that the risk for AF increased linearly with TyG over the entire TyG range; this risk was also evident when the patients were analyzed based on sex (P for nonlinear > 0.05). In addition, the correlation between TyG and AF was a consistent finding in subgroup analysis. Furthermore, ROC curve analysis showed that TyG levels combined with traditional risk factors improved the predictive value for atrial fibrillation.

Conclusion: The TyG index is useful in assessing the risk for atrial fibrillation in patients with NAFLD. Patients with NAFLD and increased TyG indices have higher risks for atrial fibrillation. Therefore, TyG indices should be assessed when managing patients with NAFLD.

Citing Articles

Influence of sodium-glucose cotransporter 2 inhibitors on the triglyceride-glucose index in acute myocardial infarction patients with type 2 diabetes mellitus.

Wang K, Fan T, He F, Li H, Fang Y, Hu G Cardiovasc Diagn Ther. 2025; 14(6):1096-1107.

PMID: 39790202 PMC: 11707467. DOI: 10.21037/cdt-24-287.

Association between TyG index and risk of carotid atherosclerosis in NAFLD patients: a retrospective cohort study.

Huang W, Wang H, Shen Z, Wang X, Yu X Front Endocrinol (Lausanne). 2024; 15:1448359.

PMID: 39229376 PMC: 11368734. DOI: 10.3389/fendo.2024.1448359.

Relationship of triglyceride-glucose index to gallstone prevalence and age at first gallstone surgery in American adults.

Wang J, Li H, Hu J, Shi R, Qin C, Chen X Sci Rep. 2024; 14(1):16749.

PMID: 39033195 PMC: 11271289. DOI: 10.1038/s41598-024-67883-0.

Correlation between serum uric acid to high-density lipoprotein cholesterol ratio and atrial fibrillation in patients with NAFLD.

Liu G, Zhang Q, Zhou M, Li B, Zhao J, Bai R PLoS One. 2024; 19(6):e0305952.

PMID: 38913677 PMC: 11195987. DOI: 10.1371/journal.pone.0305952.

Lipid-based insulin-resistance markers predict cardiovascular events in metabolic dysfunction associated steatotic liver disease.

Colantoni A, Bucci T, Cocomello N, Angelico F, Ettorre E, Pastori D Cardiovasc Diabetol. 2024; 23(1):175.

PMID: 38769519 PMC: 11106932. DOI: 10.1186/s12933-024-02263-6.

References

Wang Z, Wang Y, Liu Z, Li Q, Kong Y, Chen Y . Effect of Insulin Resistance on Recurrence after Radiofrequency Catheter Ablation in Patients with Atrial Fibrillation. Cardiovasc Drugs Ther. 2022; 37(4):705-713. DOI: 10.1007/s10557-022-07317-z. View

Maria Z, Campolo A, Scherlag B, Ritchey J, Lacombe V . Dysregulation of insulin-sensitive glucose transporters during insulin resistance-induced atrial fibrillation. Biochim Biophys Acta Mol Basis Dis. 2018; 1864(4 Pt A):987-996. DOI: 10.1016/j.bbadis.2017.12.038. View

Park K, Ahn C, Lee S, Kang S, Nam J, Lee B . Elevated TyG Index Predicts Progression of Coronary Artery Calcification. Diabetes Care. 2019; 42(8):1569-1573. DOI: 10.2337/dc18-1920. View

Bai L, Li H . Innate immune regulatory networks in hepatic lipid metabolism. J Mol Med (Berl). 2019; 97(5):593-604. DOI: 10.1007/s00109-019-01765-1. View

Hindricks G, Potpara T, Dagres N, Arbelo E, Bax J, Blomstrom-Lundqvist C . 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the.... Eur Heart J. 2020; 42(5):373-498. DOI: 10.1093/eurheartj/ehaa612. View

Yan F, Zhang X, Wang W, Ji Y, Wang P, Yang Y . The E3 ligase tripartite motif 8 targets TAK1 to promote insulin resistance and steatohepatitis. Hepatology. 2016; 65(5):1492-1511. DOI: 10.1002/hep.28971. View

Gong H, Liu X, Cheng F . Relationship between non-alcoholic fatty liver disease and cardiac arrhythmia: a systematic review and meta-analysis. J Int Med Res. 2021; 49(9):3000605211047074. PMC: 8489776. DOI: 10.1177/03000605211047074. View

Alpert M, Karthikeyan K, Abdullah O, Ghadban R . Obesity and Cardiac Remodeling in Adults: Mechanisms and Clinical Implications. Prog Cardiovasc Dis. 2018; 61(2):114-123. DOI: 10.1016/j.pcad.2018.07.012. View

Lloyd-Jones D, Wang T, Leip E, Larson M, Levy D, Vasan R . Lifetime risk for development of atrial fibrillation: the Framingham Heart Study. Circulation. 2004; 110(9):1042-6. DOI: 10.1161/01.CIR.0000140263.20897.42. View

10.

Demirci I, Haymana C, Candemir B, Meric C, Yuksel B, Eser M . Triglyceride-glucose index levels in patients with congenital hypogonadotropic hypogonadism and the relationship with endothelial dysfunction and insulin resistance. Endokrynol Pol. 2021; 72(3):232-237. DOI: 10.5603/EP.a2021.0019. View

11.

Bayman E, Dexter F . Multicollinearity in Logistic Regression Models. Anesth Analg. 2021; 133(2):362-365. DOI: 10.1213/ANE.0000000000005593. View

12.

Watt M, Miotto P, De Nardo W, Montgomery M . The Liver as an Endocrine Organ-Linking NAFLD and Insulin Resistance. Endocr Rev. 2019; 40(5):1367-1393. DOI: 10.1210/er.2019-00034. View

13.

Jiang Z, Zhu J, Shen H, Zhao S, Tang Y, Tang S . A High Triglyceride-Glucose Index Value Is Associated With an Increased Risk of Carotid Plaque Burden in Subjects With Prediabetes and New-Onset Type 2 Diabetes: A Real-World Study. Front Cardiovasc Med. 2022; 9:832491. PMC: 8927542. DOI: 10.3389/fcvm.2022.832491. View

14.

Rahman F, Kwan G, Benjamin E . Global epidemiology of atrial fibrillation. Nat Rev Cardiol. 2014; 11(11):639-54. DOI: 10.1038/nrcardio.2014.118. View

15.

Jiao N, Baker S, Chapa-Rodriguez A, Liu W, Nugent C, Tsompana M . Suppressed hepatic bile acid signalling despite elevated production of primary and secondary bile acids in NAFLD. Gut. 2017; 67(10):1881-1891. DOI: 10.1136/gutjnl-2017-314307. View

16.

Westerman S, Wenger N . Gender Differences in Atrial Fibrillation: A Review of Epidemiology, Management, and Outcomes. Curr Cardiol Rev. 2018; 15(2):136-144. PMC: 6520576. DOI: 10.2174/1573403X15666181205110624. View

17.

Targher G, Byrne C, Tilg H . NAFLD and increased risk of cardiovascular disease: clinical associations, pathophysiological mechanisms and pharmacological implications. Gut. 2020; 69(9):1691-1705. DOI: 10.1136/gutjnl-2020-320622. View

18.

Ma M, Zhi H, Yang S, Yu E, Wang L . Body Mass Index and the Risk of Atrial Fibrillation: A Mendelian Randomization Study. Nutrients. 2022; 14(9). PMC: 9101688. DOI: 10.3390/nu14091878. View

19.

Peterson L . Obesity and insulin resistance: effects on cardiac structure, function, and substrate metabolism. Curr Hypertens Rep. 2006; 8(6):451-6. DOI: 10.1007/s11906-006-0022-y. View

20.

Jian-gao F . Guidelines for management of nonalcoholic fatty liver disease: an updated and revised edition. Zhonghua Gan Zang Bing Za Zhi. 2010; 18(3):163-6. View